Item 8.01 - Other Events: Incyte Corporation announced it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (CMS) to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation. Jakafi Pricing Agreement: Under the agreement, the Company will enable state Medicaid programs to access Jakafi and Jakafi XR at prices…

Our analysis rates this filing NEUTRAL. The moderate concern level (3.8/10) reflects a balanced picture with manageable regulatory headwinds. While the CMS pricing agreement introduces real revenue uncertainty for Jakafi products, the company's proactive engagement, secured exemption from future…

Concern level: MODERATE (3.8/10). Key factors: CMS Medicaid pricing agreement introduces revenue uncertainty for Jakafi/Jakafi XR (severity 5/10) - key revenue driver subject to international reference pricing constraints; Regulatory exemption from GUARD/GLOBE models is contingent and subject to future policy changes (severity 4/10) - near-term relief but long-term regulatory landscape remains…

Notable risk changes: Incyte entered into CMS agreement enabling state Medicaid access to Jakafi/Jakafi XR at international reference pricing levels - represents proactive regulatory accommodation; Company secured exemption from proposed CMS pricing mandates (GUARD and GLOBE models) - reduces future regulatory pricing pressure risk; Company explicitly states agreement 'does not expect to affect 2026 financial…